Skip to main content
hello world

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Globe Newswire - Fri Dec 10, 2021

- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met

- The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1

Read more at globenewswire.com